Best Genomics Companies in England, United Kingdom

Provider of cell-free DNA technology platform for genetic medicine application. It leverages a proprietary technology platform and enzymatic manufacturing solutions to develop doggy bone DNA vectors optimized for use in advanced genetic medicines. The platform supports a range of applications which includes mRNA therapeutics, AAV and lentiviral vectors, gene editing, non‑viral therapies, and DNA vaccines.

Funding rounds

• Sep 2025Grant (prize money)$714.1K
• Nov 2022Grant (prize money)—
• Jan 2021Series B$178.5M
• Apr 2017Series A$3M

Founders & team

Jonny OhlsonFounder & Co-CEOAntonio MarquesChief Operating OfficerKaren FallenCo-CEO

Investors

Bridford Group, Novator Partners, Gates, Downing, Military Health, Columbus Venture Partners

Tech stack

AddtoanyAddtoany Share ButtonsAnime.JsCloudflareCloudflare Bot ManagementContentsquare

Developer of a method to profile the biology of coronary artery. It is building cohorts to endotype the disease for the first time. The approach enables the identification of new disease-specific drug targets. This paves the way for precision medicine for patients with coronary artery disease.

Manufacturer of portable and benchtop devices for real-time DNA sequencing. These instruments utilize nanopore sensing technology to analyze native DNA and RNA molecules. The hardware supports various workflows, including library preparation and data analysis through integrated software tools. Applications include genomic research, microbial identification, and transcriptomics. The technology enables the detection of genetic variations and structural changes in biological samples.

Funding rounds

• Aug 2024Post IPO$64.2M
• Oct 2023Post IPO$84.5M
• May 2021Series H$270.5M
• Oct 2020Series G$110.1M

Founders & team

Hagan BayleyCo-FounderGordon SangheraCo-FounderFrancis ParysCEO

Investors

Illumina, Novo Holdings, Europa, M&G, Temasek, Wellington

Tech stack

AcuityadsAmazon CloudfrontAmazon S3Amazon Web ServicesApple Icloud MailAuthorize.Net

Provider of a platform for mammalian cell engineering. The company provides plasmid and DNA component products and a plasmid technology called SnapFast. The company is designing DNA sequences, optimizing the expression of proteins, developing cell lines, and improving viral delivery systems. It integrates bioinformatics and gene-editing technology to create a streamlined workflow for cell line production.

Funding rounds

• Jul 2025Series A$1M
• May 2020Series A$3.7M
• Mar 2019Series A$8.6M
• Aug 2017Series A$10.3M

Founders & team

Len SeymourCo-Founder

Investors

Mercia, Canaccord Genuity Group, Invesco, Gov, HSBC Bank

Digital platform focused on decoding the causal biology behind genetic variations to accelerate drug discovery. The company uses proprietary GenLink 3D multi-omics platform analyzes genome folding and links disease-associated variants to target genes across the entire human genome, enabling faster identification of high-confidence therapeutic targets for common diseases like autoimmune conditions.

Funding rounds

• Sep 2025Series A$19M

Founders & team

Peter FraserCo-FounderStefan SchoenfelderCo-Founder & Chief Scientific Advisor

Investors

BGF, Parkwalk, Meltwind Advisory

Tech stack

Amazon Web ServicesCloudflareCloudflare Bot ManagementCookieyesFramer SitesGoogle Font Api

Provider of a platform for genome and polymer synthesis. The company pioneered the development of methods for reprogramming the genetic code of living organisms that are resistant to a wide variety of viruses, can be programmed to make synthetic, polymers, and even perform entirely new functions. It has applications across a range of industries including novel therapeutics and antibiotics enhanced agriculture, manufacturing, and materials.

Funding rounds

• Mar 2025Series A—
• Sep 2024Series A$58M
• Aug 2022Seed$15M

Founders & team

Ola WlodekCEO

Investors

Ahren, Amadeus Capital, OMX Ventures, General Inception, Paladin Capital, Fine Structure Ventures

Tech stack

BamboohrCloudflareGoogle AnalyticsGoogle Tag ManagerHstsMicrosoft 365

AI-based RNA drug development platform for researchers. The company harnesses the power of combinatorial chemistry and AI to transform RNAi drug development into a programmable process against influenza and SARS-CoV-2.

Funding rounds

• Apr 2025Grant (prize money)$3M
• Feb 2025Grant (prize money)$320K
• Aug 2022Seed$18M
• Aug 2022Grant (prize money)$4M

Founders & team

Shaul IlanCo-FounderGreg HannonCo-FounderYaniv ErlichCo-Founder & CEO

Investors

Gates, Kindred Capital, Entree Capital, Harel Group, Gov, NFX

Tech stack

BootstrapCdnjsCloudflareContact Form 7Core-JsGoogle Analytics

Enara Bio is developing a T-cell based cancer-cell interface for therapeutics. The company is involved in the immune interface for cancer biology to develop and characterize immunotherapy targets, like dark antigens derived from the genomic dark matter or antigens presented by the cancer-specific MR1 receptor. The company offers proprietary TCR-directed T-cell therapies to target tumor homogeneity and cancer vaccines to generate polyclonal autologous ex vivo stimulation of T-cell products.

Funding rounds

• Oct 2024Series B$32.5M
• May 2021Series A$16.3M
• Nov 2019Series A$17.5M
• Apr 2018Seed$7.8M

Founders & team

Kevin PojasekCEO & PresidentHouman Ashrafian

Investors

M Ventures, Pfizer Ventures, Crick, RA Capital Management, Samsara BioCapital, SV Health Investors

Tech stack

Craft CmsDocusignGodaddyGoogle AnalyticsNginxOpen Graph

Developer of genomic-based cancer diagnostic platform. It offers a platform technology based on a non-invasive blood test that captures the unmodified locations of the genome and analyzes the changes that occur during cancer.

Provider of point of care molecular diagnostics platform for genotyping and sequence analysis. The company offers MT-RNR1 ID Kit, a pharmacogenetic test to prevent antibiotic induced deafness in infants, and Genedrive HCV ID Kit is used to screen for hepatitis C and COVID-19.

Funding rounds

• Apr 2025Post IPO$1.6M
• Nov 2018Post IPO$7.7M

Founders & team

Christopher PottenCo-FounderCatherine BoothCo-FounderJames CheekCEO

Investors

Calculus Capital, Global Health Investment Fund

Developer of microbial strains for the treatment of human metabolic diseases. The company's proprietary platform technologies include OptiScreen and OptiBiotic designed to identify metabolic pathways and compounds that impact human physiology and bring potential health benefits. It can be used as food ingredients, supplements, or active compounds for the prevention and management of human metabolic diseases such as obesity, cholesterol and lipid distribution, and diabetes.

Provider of genomic risk assessment and prevention platform. This platform uses advanced polygenic risk scores and data science to predict individual risk of common diseases. It offers personalized tools and guidance for individuals, employers, and healthcare providers. The platform also assists life sciences companies in accelerating drug discovery and optimizing clinical trial design. The company's work contributes to more personalized and precise healthcare, ultimately aiming to improve health outcomes and reduce the cost of common diseases.

Funding rounds

• Jan 2024Series C$44.5M
• Mar 2021Series B$30M
• Dec 2018Series B$10.1M
• Aug 2018Series B$32.3M

Founders & team

Rebecca HFounder & PrincipalGil McVeanCo Founder & DirectorPeter DonnellyCo-Founder & CEO

Investors

F-Prime Capital, Infinity Investment Partners, MassMutual Ventures, Foresite Capital, Oxford Science Enterprises, Lansdowne Partners

Tech stack

Apple Icloud MailCloudflareCloudflare Bot ManagementCookiebotGoogle AnalyticsGoogle Tag Manager